Fujimura et al. [35] presented a case of palmoplantar MF treated with MOG, suggesting that the decrease in CCL22 levels paralleled disease activity and could be considered a response biomarker, associated not only with bexarotene but also with MOG. This evidence concerns the gene MOG and mycosis fungoides.